Involvement of cAMP response element-binding protein in the regulation of cell proliferation and the prolactin promoter of lactotrophs in primary culture adenosine 3Ј,5Ј-cyclic monophosphate; dopamine; insulin-like growth factor I ADENOSINE 3Ј,5Ј-CYCLIC MONOPHOSPHATE (cAMP) stimulates or inhibits cell proliferation, depending on the cell type. cAMP action is mediated mostly by its downstream effector, protein kinase A (PKA). PKA-dependent cAMP signaling for proliferation involves activation of the transcription factor cAMP response element (CRE)-binding protein (CREB) (29) or the Rap1-mediated kinase cascade (36) . PKA acts directly on CREB and causes phosphorylation of the serine residue at position 133 (Ser 133 ), which is an essential step for CREB activation and dimerization (14) . The activation by PKA endows CREB with the ability to bind to a CRE sequence in the promoters of numerous target genes and stimulate their transcription (46) . The CREB target genes related to cell proliferation include c-fos, cyclins A and D, and proliferating cellular nuclear antigen (29, 47) . CREB, originally identified as a transcription factor activated by the cAMP-PKA pathway, is also phosphorylated at the same Ser 133 by many other protein kinases, including ribosomal S6 kinase 2 (44), mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (40) , calcium/calmodulin-dependent kinases (26) , and protein kinase B/Akt (10) . The fact that CREB is phosphorylated by a variety of protein kinase-mediated signaling pathways suggests that CREB is a convergent molecule for regulating essential cell functions such as cell proliferation, differentiation, and survival (35) . Involvement of CREB in the regulation of cell proliferation has been shown in vivo and in vitro in somatotrophs (37) , vascular smooth muscle cells (41) , developing thymocytes (15) , and cell lines from thyroid follicles (43) and myeloid leukemia (34) .
However, the PKA-CREB pathway is not the sole pathway for mediating the mitogenic signal of cAMP (36) . PKA activates Rap1, a member of the Ras superfamily of small G proteins that, in turn, stimulates and inhibits the activity of MAPK kinase kinases such as B-Raf and Raf-1, respectively, leading to altered activity of the MAPK extracellular signalregulated kinase (ERK) (33, 42) that is critical for growth factor-induced proliferation. Importantly, Rap1 is also activated by cAMP through the cAMP-guanine nucleotide exchange factor (GEF) in a PKA-independent manner (9, 19) . Activation of Rap1 by the cAMP-GEF pathway activates the MAPK pathway (22) and has been implicated in cell proliferation in several cell types (13, 17) . Furthermore, cAMP also activates phosphoinositide 3-kinase and its downstream molecule Akt in PKA-dependent and -independent manners to stimulate proliferation in thyroid and ovarian granulosa cells (2, 5, 32) . Thus, cAMP utilizes multiple signaling pathways to regulate cell proliferation in a cooperative manner.
There are several lines of evidence indicating that cAMP is a positive regulator of the proliferation of pituitary lactotrophs and mediates the action of hypothalamic hormones on proliferation. First, we have previously shown that increased intracellular cAMP concentrations caused by treatment with a membrane-permeable cAMP analog or forskolin, an adenylate cyclase activator, stimulate proliferation of lactotrophs in primary culture in a PKA-dependent manner (38, 45) , although an inhibitory action of cAMP has been reported in the somato-mammotroph cell line GH 3 (18) . Second, the hypothalamic hormone dopamine and its agonists, which inhibit markedly lactotroph functions, including the secretion and synthesis of prolactin (PRL) and cell proliferation (1), lower intracellular cAMP concentrations (28, 39) . Third, forskolin-induced lactotroph proliferation is suppressed by treatment with bromocriptine, a dopaminergic agonist, suggesting that the antimitogenic action of dopamine is, at least in part, mediated by inhibition of cAMP production (38) . In addition to regulation by the cAMP-PKA pathway, pituitary-intrinsic growth factors and their signaling kinase cascade, the MAPK, are other major regulators of lactotroph proliferation. Interestingly, we (38, 45) have previously shown that insulin-induced lactotroph proliferation is blocked by the PKA inhibitors H89 and KT5720, suggesting that there is a functional interaction between the cAMP-PKA and growth factor-MAPK pathways.
The role of CREB in the regulation of lactotroph functions is poorly understood. All studies published to date have been restricted to investigating the involvement of CREB in the regulation of PRL gene expression using GH 3 cells (6, 24) . Therefore, we used normal lactotrophs in primary culture and investigated 1) whether bromocriptine inhibits CRE-mediated transcription and CREB phosphorylation in lactotrophs, 2) whether expression of a dominant-negative CREB mutant suppresses forskolin-or insulin-like growth factor I (IGF-I)-induced stimulation of PRL promoter activity and lactotroph proliferation, and 3) whether IGF-I increases intracellular cAMP concentrations and CREB phosphorylation in lactotrophs.
MATERIALS AND METHODS
Plasmids and adenovirus vectors. Adenovirus vectors were produced using the Adeno-X Expression and Adeno-X Tet-On Expression systems according to the manufacturer's protocol (Clontech Laboratories, Mountain View, CA). The adenovirus vector Ad-TRE/ MCREB.Tag expresses a dominant-negative CREB mutant (MCREB) (14) and a 6ϫHis tag at its NH2 terminus in a tetracycline-regulated manner. A 1.3-kb fragment of the MCREB cDNA was excised by NheI and SwaI digestion of pcDNA-MCREB, a plasmid originating from RSV-M1CREB, and subcloned into the pTRE-Shuttle2 vector (Clontech Laboratories) at the NheI/EcoRV sites. A 6ϫHis tag was then added at the NH2 terminus of MCREB of the pTRE-Shuttle2 using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and primers of 5Ј-caccggtgactagatgcatcaccaccaccatcacaccatggactctggag-3Ј and its antisense sequence. A fragment containing the cDNA for 6ϫHis-tagged MCREB was isolated from the pTRE-Shuttle2 by digestion with I-CeuI and PI-SceI and inserted into a site created with the same restriction enzymes in Adeno-X viral DNA, a replication-incompetent adenoviral genome. The Adeno-X carrying 6ϫHis-tagged MCREB was transfected into HEK-293 cells using the FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) for virus production, and the recombinant adenoviruses were further propagated by serial infection in HEK-293 cells. The adenoviruses obtained were purified with the Adeno-X Virus Purification kit (Clontech Laboratories) and concentrated with the Centricon Centrifugal Filter Unit (Millipore, Bedford, MA). The titer of adenovirus vectors (infectious units) was determined using the Adeno-X Rapid Titer kit (Clontech Laboratories). Ad-TRE/wtCREB, an adenovirus vector expressing wild-type CREB, was produced from pcDNA-CREB by a procedure similar to that for Ad-TRE/ MCREB.Tag production. Ad-TRE/␤-gal and Ad-Tet.On, adenoviruses expressing ␤-galactosidase in a tetracycline-regulated manner and rTetR-VP16, respectively, were purchased from Clontech Laboratories.
To produce an adenovirus vector expressing the luciferase reporter gene driven by a promoter containing the consensus CRE (Ad-CRE/ Luc) or serum response element (SRE) sequence (Ad-SRE/Luc), the pCRE-Luc and pSRE-Luc plasmids (Mercury Pathway Profiling System; Clontech Laboratories) were digested with BamHI and NotI, and the resultant fragment containing the CRE-or SRE-driven luciferase gene was subcloned into a BamHI-and NotI-digested fragment of a pTRE-Shuttle2 vector lacking its tetracycline-responsive expression cassette (positions 34 -1,582), named pTRE-Shuttle2-NruI.MCS. SmaI. pTRE-Shuttle2-NruI.MCS.SmaI was constructed by excising the multiple cloning region from the pSL1180 vector (Amersham Biosciences, Arlington Heights, IL) using NruI and SmaI and then inserting it into a BglII-digested and end-blunted pTRE-Shuttle2 vector. To produce an adenovirus vector carrying a PRL promoter activity reporter gene (Ad-Prl/Luc), a 3.2-kb fragment of the 5Ј-flanking region of the rat PRL gene (positions Ϫ3,221 to ϩ33) was isolated from pSV2A-Prl/Luc (a generous gift from Dr. Harry Elsholtz, University of Toronto, Toronto, ON, Canada) by digestion with BamHI and HindIII and subcloned into the pGL3-Basic vector (Promega, Madison, WI) at the BglII/HindIII sites. A BamHI-and NotI-digested fragment of the pGL3 vector containing the reporter gene was inserted into the pTRE-Shuttle2-NruI.MCS.SmaI vector at a site created by the same restriction enzymes. The pTRE-Shuttle2-NruI.MCS.SmaI vector containing the CRE-, SRE-, or PRL promoterdriven luciferase gene was digested with I-CeuI and PI-SceI, and the reporter gene was inserted into Adeno-X viral DNA. The lactotrophspecific expression of luciferase by infection with Ad-Prl/Luc was confirmed by selective localization of luciferase-immunoreactivity in some PRL-immunoreactive pituitary cells, as demonstrated by double immunostaining for luciferase and PRL.
Cell culture and virus infection. Experiments were conducted in accordance with the guidelines of the Ethics Committee of Animal Experiments of the University of Yamanashi and were approved by the committee. Seven-week-old female Wistar rats purchased from Japan SLC (Shizuoka, Japan) were used to obtain anterior pituitary cells for primary culture. Anterior pituitary cells were dispersed as described previously (20) . A 100-l aliquot of pituitary cell suspension containing 2.0 ϫ 10 5 cells in a 1:1 mixture of DMEM and Ham's nutrient mix F-12 without phenol red and containing 15 mM HEPES, penicillin, and streptomycin (DMEM-F-12) was plated in poly-D-lysine-coated culture dishes. For infection with adenovirus vectors, Ad-Tet.On in combination with either Ad-TRE/MCREB.Tag or Ad-TRE/␤-gal and, in reporter assay experiments, Ad-Prl/Luc or Ad-CRE/Luc was added into the cell suspension at appropriate multiplicities of infection (MOIs). The cells were subsequently allowed to attach to the surface of the dishes in a humidified CO2 incubator for 1 h. The pituitary cells were then flooded with 2 ml of DMEM-F-12 containing 500 ng/ml insulin and precultured at 37°C in a humidified atmosphere of 5% CO2 and 95% air for 1 day. After 1 day of preculture, the pituitary cells were washed with DMEM-F-12 to remove adenoviruses, and cultures were initiated with a serum-free, chemically defined medium (20) in which doxycycline (Clontech Laboratories) was added at a concentration of 10 g/ml to induce the reverse Tet repressor protein and thereby either MCREB or ␤-galactosidase protein. Cultured pituitary cells were treated with mitogens such as forskolin, IGF-I, and bromocriptine (all from Sigma Chemical, St. Louis, MO). For labeling proliferating pituitary cells, the cultured cells were treated with 200 M 5-bromo-2Ј-deoxyuridine (BrdU; Sigma Chemical) for 3 h prior to the end of culture.
Immunostaining. To determine the BrdU-labeling index, pituitary cells labeled with BrdU were detached from culture dishes at the end of culture by trypsin treatment. The cells were attached to poly-D-lysine-coated glass slides by centrifugation, using a cytocentrifuge (SC-2; Tomy, Tokyo, Japan), and fixed with ice-cold methanol for 30 min. The pituitary cells attached to glass slides were double immunostained for BrdU and PRL as described previously (20) . Immunostained slides were covered with PermaFluor (Immunon, Pittsburgh, PA) and examined with a fluorescence microscope (BX50-FLA; Olympus, Tokyo, Japan) equipped with a dual-band mirror unit for FITC and Texas Red (U-DM-FI/TX). A total of 1,000 PRL-immunoreactive cells were examined in randomly chosen fields for each slide to determine the BrdU-labeling index, which was the percentage of cells immunoreactive for both PRL and BrdU of the total PRLimmunoreactive cells counted.
For double immunostaining for phosphorylated CREB (pCREB) and PRL, pituitary cells cultured on dishes were fixed with 1.8% paraformaldehyde in 0.1 M phosphate buffer for 10 min and rinsed with Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T). The pituitary cells were permeabilized with TBS containing 1% Tween 20 for 30 min, followed by blocking of endogenous peroxidase with 3% hydrogen peroxide in phosphate-buffered saline for 10 min. After blocking nonspecific binding by using the 0.5% blocking reagent supplied in the TSA Fluorescence System (NEL701A; PerkinElmer, Boston, MA) for 30 min, the pituitary cells were immunostained for pCREB and PRL using the following reagents: 1) a monoclonal rabbit anti-pCREB antibody (Cell Signaling Technology, Beverly, MA) at a 1:100 dilution for 48 h at 4°C, 2) an FITC-labeled donkey anti-rabbit IgG antibody (Amersham Biosciences) at a 1:100 dilution for 1 h, 3) a peroxidase-labeled sheep anti-fluorescein antibody (Roche Diagnostics) at a 1:200 dilution for 1 h, 4) FITC-labeled tyramide (PerkinElmer) at a 1:50 dilution for 10 min, 5) a monoclonal mouse anti-rat PRL antibody (QED Bioscience, San Diego, CA) at a 1:10,000 dilution for 1 h, and 6) an Alexa fluor 594-labeled anti-mouse IgG antibody (Molecular Probes, Eugene, OR) at a 1:100 dilution for 1 h. Fluorescence images of the immunostained pituitary cells were captured with a digital charge-coupled device camera (DP50; Olympus) and stored in a personal computer. pCREB immunoreactivity was quantified by measuring the fluorescence intensity of nuclear FITC with Photoshop imaging software (Adobe Systems, San Jose, CA), and a cell with a fluorescence intensity higher than a level of 60 was defined as a pCREB-immunoreactive cell. Pituitary cells that were immunoreactive for both pCREB and PRL were counted in a total of 200 PRL-immunoreactive cells.
To validate the adenovirus-mediated expression of MCREB protein, paraformaldehyde-fixed pituitary cells were immunostained for CREB or the 6ϫHis tag with 1) a rabbit anti-CREB antibody (Cell Signaling Technology) at a 1:2,000 dilution or a rabbit anti-His-Tag antibody (Cell Signaling Technology) at a 1:20,000 dilution for 150 min, 2) a peroxidase-labeled polymer reagent (Envisionϩ; Dako Japan, Tokyo, Japan) for 1 h, and 3) cyanine 5-labeled tyramide (PerkinElmer) at a 1:50 dilution for 10 min. To verify the lactotrophspecific expression of the reporter luciferase gene, pituitary cells infected with Ad-Prl/Luc were attached to glass slides after redispersion and fixed with ice-cold methanol. The pituitary cells were permeabilized, blocked for endogenous peroxidase and nonspecific binding, and then subjected to double immunostaining for luciferase and PRL with the following reagents: 1) a rabbit anti-luciferase antibody (Sigma Chemicals) at a 1:12,000 dilution overnight at 4°C, 2) a peroxidase-labeled donkey anti-rabbit IgG antibody (crossabsorbed; Jackson Immunoresearch Laboratories, West Grove, PA) at a 1:200 dilution for 1 h, 3) cyanine 5-labeled tyramide at a 1:50 dilution for 10 min, 4) a guinea pig anti-rat PRL antibody (GP-4) at a 1:500 dilution for 1 h, 5) a biotinylated donkey anti-guinea pig IgG antibody (cross-absorbed; Jackson Immunoresearch Laboratories) at a 1:200 dilution for 1 h, and 6) an Alexa fluor 350-labeled streptavidin (Molecular Probes) at a 1:200 dilution for 1 h.
Quantitative real-time polymerase chain reaction. Total pituitary RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol and treated with RNase-free DNase I (Qiagen). RNA (0.5 g) was reverse-transcribed using oligo(dT)20 primer and ReverTra Ace reverse transcriptase (Toyobo, Osaka, Japan). Reverse transctiptase reactions were amplified on ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA) using SYBR Green Real-Time PCR Kit (Toyobo). The following primers were used: PRL forward, 5Ј-TCCTGGAATGAC-CCTCTGTTTC-3Ј; PRL reverse, 5Ј-GTTCCTCAATCTCTTTGGCT-CTTG-3Ј; ␤-actin forward, 5Ј-GACAGGATGCAGAAGGAGAT-TACTG-3Ј; ␤-actin reverse, 5Ј-AGAGCCACCAATCCACACAGA-3Ј.
The final PCR products were subjected to thermal denaturation to ensure that the product denatured as a uniform peak. PRL mRNA levels were calculated by the 2 Ϫ⌬⌬CT method using ␤-actin as an endogenous reference.
Immunoblotting. Pituitary cells were lysed with 100 l of ice-cold lysis buffer composed of 20 mM Tris, pH 7.6, 137 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and protease inhibitor cocktail (aprotinin, bestatin, leupeptin, and pepstatin A, sc-24948; Santa Cruz Biotechnology, Santa Cruz, CA) for 15 min at 4°C. The cell lysates were incubated on ice for 30 min with vortexing every 10 min, and whole cell extract of soluble protein was obtained by centrifugation at 17,500 g for 15 min at 4°C. Protein concentration of the supernatants was determined using the BCA Protein Assay kit (Pierce, Rockford, IL). Supernatants containing equal amounts of total protein (6 g) were denatured in 2ϫ sample buffer composed of 125 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 5% ␤-mercaptoethanol, and 0.2% bromophenol blue for 5 min at 99°C and electrophoresed on a 12.5% SDS-polyacrylamide gel. Separated proteins were transferred to the polyvinylidene difluoride membrane Hybond-P (Amersham Biosciences). The membrane was blocked for 1 h with 5% nonfat dry milk in TBS-T and then subjected to incubation with a rabbit anti-CREB antibody (no. 238461; Calbiochem, Darmstadt, Germany) at a 1:2,000 dilution, at which overexpressed MCREB and wild-type (wt)CREB but not endogenous CREB were detected, or a mouse anti-␤-actin antibody (A-5441; Sigma Chemical) at a 10,000 dilution in TBS-T containing 5% BSA at 4°C overnight. The primay antidodies were labeled with a horseradish peroxidase-conjugated anti-rabbit or mouse IgG antibody (1:10,000 dilution in TBS-T; Amersham Biosciences). The membrane was reacted with the reagents of the ECL Plus Western Blotting Detection System (Amersham Biosciences) according to the manufacturer's instructions, and the signal was detected with a luminoimage analyzer (LAS-1000 plus; Fuji Photo Film, Tokyo, Japan).
Luciferase reporter assay. Pituitary cells were lysed for luciferase assays with 400 l of the reporter lysis buffer (Promega) by repeated pipetting according to the manufacturer's protocol. The cell lysates were vortexed for 10 s and centrifuged at 18,000 g for 2 min. Forty-microliter aliquots of the supernatants were assayed for luciferase activity using the Luciferase Assay System (Promega). Light intensity was measured with a luminometer (BLR-201; Aloka, Tokyo, Japan) and is expressed in terms of relative luciferase units.
cAMP assay. Intracellular cAMP concentrations were determined using an enzyme immunoassay kit (Assay Designs, Ann Arbor, MI). Pituitary cells were treated with 300 l of 0.1 N HCl for 15 min, and cell lysates were centrifuged at 15,000 g for 5 min. The supernates were acetylated with acetic anhydride and triethylamine and assayed for cAMP. The minimum detectable concentration for the cAMP was 0.016 pmol/assay tube (90% B/B 0). The intra-assay coefficient of variation was 6.4%.
Statistical analysis. Experiments were replicated at least three times with separate batches of cell preparations. Differences between groups were statistically analyzed using one-way ANOVA followed by Fisher's protected least significant difference test.
M forskolin increased PRL promoter-regulated luciferase reporter activity and lactotroph proliferation, as determined by BrdU labeling (Fig. 1, A and B) . Pretreatment with 10 nM bromocriptine 1 h earlier significantly inhibited basal and forskolin-induced PRL promoter-luciferase activity by 59 and 58%, respectively, compared with vehicle pretreatment (P Ͻ 0.05). Bromocriptine was also effective in inhibiting basal and forskolin-induced lactotroph proliferation by 78 and 76%, respectively (P Ͻ 0.05), as shown previously (38) . To investigate whether bromocriptine alters CRE-mediated transcription, CRE-luciferase activity was determined in vehicle-and bromocriptine-treated cells by infection with Ad-CRE/Luc, an adenovirus carrying a luciferase reporter gene driven by two tandem repeats of the consensus CRE sequence. CRE-luciferase activity was markedly increased by forskolin treatment (Fig. 1C) . Basal and forskolin-induced CRE-luciferase activity was significantly inhibited by bromocriptine pretreatment by 22 and 79%, respectively (P Ͻ 0.05). Because the CRE-luciferase activity measured was attributed not only to lactotrophs but also in part to other pituitary cell types, we further investigated whether bromocriptine alters lactotroph-specific activation of CREB upstream of CRE regulation. We determined the proportion of pCREB-immunoreactive (pCREB-ir) lactotrophs with double-immunocytochemical staining for PRL and pCREB using an antibody that specifically recognizes phosphorylation of Ser 133 of CREB. The double-immunocytochemical staining revealed nuclear pCREB immunoreactivity in a proportion of pituitary cells (Fig. 2A) . In parallel to the changes in CRE-luciferase activity, the percentage of pCREB-ir lactotrophs was increased by forskolin treatment, and the forskolin-induced increase was significantly inhibited by bromocriptine pretreatment by Ͼ80% compared with vehicle pretreatment (P Ͻ 0.05; Figs. 1D and 2, B-D) .
Adenovirus-mediated and tetracycline-regulated expression of MCREB in pituitary cells. We used a dominant-negative form of CREB, MCREB, to inhibit CREB function. MCREB, in which Ser 133 is substituted with Ala (14) , can bind to the CRE sequence but does not transactivate CREB-responsive genes and thereby acts as a CREB inhibitor via direct competition with endogenous CREB or other CREB family members.
To verify the appropriate expression of MCREB in a tetracycline-regulated manner by an adenovirus vector, pituitary cells coinfected with Ad-TRE/MCREB.Tag and Ad-Tet.On were treated with or without doxycycline, a tetracycline analog, for 2 days and subjected to immunocytochemical studies. Because no antibodies available can immunologically distinguish MCREB from endogenous CREB, MCREB expression was verified by two indirect methods. The first method involved immunostaining with a CREB antibody at a dilution at which MCREB overexpressed by the cytomegalovirus promoter, but not endogenous CREB, was detected. This technique revealed doxycycline-dependent specific immunoreactivity in the nuclei of virus-infected pituitary cells (Fig. 3, B and C) . Second, identical results were obtained by immunostaining with an antibody against the 6ϫHis tag, which was added at the NH 2 terminus of MCREB (Fig. 3, D and E) . Furthermore, MCREB expression was functionally verified by examining the effect of adenovirus infection on forskolin-induced CRE-luciferase activity. In addition to Ad-Tet.On and Ad-TRE/MCREB.Tag at varying MOIs, pituitary cells were infected with Ad-CRE/Luc. Reporter assays revealed that forskolin-induced CRE-luciferase activity was decreased in an Ad-TRE/MCREB.Tag dosedependent manner only in the presence of doxycycline (Fig. 4A) . MCREB expression also inhibited the luciferase activity of the cytomegalovirus promoter known to contain CREs (data not shown) but did not alter fetal bovine seruminduced SRE activity, indicating CRE specificity of the effect of Ad-TRE/MCREB.Tag (Fig. 4B) . On the basis of these results, an MOI of 2 was chosen as an optimum dose of Ad-TRE/MCREB.Tag and Ad-Tet.On for blocking CREB activation in the subsequent experiments.
Effects of MCREB expression on PRL promoter activity.
MCREB was expressed to mimic the suppression of CREluciferase activity and CREB activation observed in bromocriptine-treated lactotrophs. Treatment of Ad-TRE/␤-galand Ad-Tet.On-coinfected pituitary cells with forskolin increased PRL promoter activity approximately fourfold above the basal level (Fig. 5A) . Forskolin-induced PRL promoter activity was not affected by expression of ␤-galactosidase induced by doxycycline treatment. MCREB expression induced by Ad-TRE/MCREB.Tag and Ad-Tet.On coinfection and doxycycline treatment significantly inhibited basal and forskolin-induced PRL promoter activity by 85 and 92%, respectively, compared with Ad-TRE/MCREB.Tag-infected controls without doxycycline (P Ͻ 0.05). Similar inhibitory effect of MCREB expression was also found in PRL mRNA expression (Fig. 5B) . To determine the specificity of the MCREB inhibition of PRL promoter activity, the antagonistic effect of the expression of wild-type CREB was examined in (C and E) . The pituitary cells were fixed with paraformaldehyde and subjected to immunocytochemical studies with an antibody against CREB at a 1:2,000 dilution (A-C), at which overexpressed MCREB but not endogenous CREB was detected, or an antibody against the 6ϫHis tag (D and E), with which 6ϫHis added at the NH2 terminus of MCREB was detected. Immunostained pituitary cells were observed using phase-contrast microscopy (A-E, left) or fluorescence microscopy (A-E, right) . Arrows in C and E indicate CREB-or 6ϫHis-immunoreactive pituitary cells, respectively. Scale bar, 20 m. (Fig. 5C ). Wild-type CREB expression significantly raised low levels of basal and forskolin-induced PRL promoter activity in MCREB-expressed pituitary cells (P Ͻ 0.05), but the effect of wild-type CREB expression remained partial restoration (Fig.  5D) , which may be due to a less competitive manner of MCREB inhibition.
Effects of MCREB expression on lactotroph proliferation. Forskolin treatment of pituitary cells coinfected with Ad-TRE/ ␤-gal and Ad-Tet.On significantly increased lactotroph proliferation 4.2-fold (P Ͻ 0.05; Fig. 6A ). Neither expression of ␤-galactosidase induced by doxycycline treatment of these infected cells nor infection with Ad-TRE/MCREB.Tag and Ad-Tet.On had a significant effect on forskolin-induced proliferation. MCREB expression induced by doxycycline treatment of the Ad-TRE/MCREB.Tag-infected cells had a marked inhibitory effect on basal proliferation (P Ͻ 0.05). In addition, MCREB expression also blocked forskolin-induced proliferation (P Ͻ 0.05).
Because IGF-I is another major regulator of lactotroph proliferation and the IGF-I-MAPK pathway has been suggested to interact with the cAMP-PKA pathway (38, 45) , the effects of MCREB expression on IGF-I-induced lactotroph proliferation were also studied. Treatment with 20 ng/ml IGF-I increased lactotroph proliferation threefold in pituitary cells coinfected with Ad-TRE/␤-gal and Ad-Tet.On regardless of doxycycline treatment (Fig. 6B) . Coinfection of pituitary cells with Ad-TRE/MCREB.Tag and Ad-Tet.On alone did not affect IGF-I-induced proliferation, whereas MCREB expression induced by treatment of infected cells with doxycycline attenuated the fold increase in IGF-I-induced proliferation by 54% (P Ͻ 0.05).
Lactotroph CREB phosphorylation in IGF-I-treated pituitary cells.
The finding that MCREB inhibited IGF-I-induced lactotroph proliferation raised the possibility that IGF-I-induced lactotroph proliferation is mediated by activation of the cAMP-PKA-CREB pathway. Therefore, we determined whether treatment of pituitary cells with IGF-I increases intracellular cAMP concentrations. Treatment with forskolin, as a positive control, markedly increased intracellular cAMP concentrations at both 20 min and 1 h (P Ͻ 0.05), whereas IGF-I treatment did not alter them at either time (Fig. 7A ). Next, we tested whether IGF-I activates lactotroph CREB without changes in cAMP concentration, because CREB has been shown (29) to be activated in response to growth factors. The percentage of pCREB-ir lactotrophs significantly increased 20 min after forskolin treatment and reached a peak with a 10-fold increase at 3 h (P Ͻ 0.05) that lasted Յ9 h (Fig. 7B) . IGF-I treatment also increased the percentage of pCREB-ir lactotrophs but was not effective as forskolin treatment; a 2.4-fold increase was observed only at 20 min and 1 h (P Ͻ 0.05).
DISCUSSION
For physiological studies, primary cultures of normal cells are superior to cell lines, but gene transfer using conventional methods is difficult to achieve for these cells. To express a dominant-negative form of CREB and reporter genes we used adenovirus vectors, which have proved efficient for expressing proteins in normal pituitary cells in primary culture (3, 30) . MCREB expression was effective in inhibiting PRL promoter activity and lactotroph proliferation, suggesting that CREB plays a critical role in regulating the function of pituitary lactotrophs. However, it should be noted that the effects of MCREB found in the present study could be partly due to blockade of transcriptional activities of other CREB family members, such as CRE modulator and activating transcription factor 1, because the consensus CRE sequence to which MCREB binds is also a site targeted by these CREB family members (12, 16) .
In previous studies using GH 3 cells, there have been conflicting results regarding the effect of expression of dominantnegative forms of CREB on cAMP-activated PRL promoter activity. A dominant-negative form of CREB, in which residues 1-243 of the transactivation domain were deleted, did not affect cAMP-induced activation of a reporter gene directed by a 0.6-kb PRL promoter region (24) , whereas KCREB, a mutant form of CREB with Arg 287 substitution with Leu, inhibited cAMP-induced activation of a shorter PRL promoter (6) . The results of the present study demonstrate that MCREB expression in lactotrophs in primary culture markedly suppresses basal activity and forskolin-induced activation of a 3.2-kb PRL promoter. These results, which are consistent with the results of MCREB inhibition of endogenous PRL mRNA expression, suggest that CREB is closely involved in maintenance of basal activity and cAMP-activation of the PRL promoter, at least in normal lactotrophs. Most functional CREs are located within 200 nucleotides of the transcription start site (47) . There is a half-CRE sequence located at positions Ϫ99 to Ϫ92 in the proximal region of the PRL promoter. However, no significant CREB binding has been detected in the proximal PRL promoter containing this half-CRE sequence (21, 24) . Given these findings, CREB or a related protein may bind to a CRE-like sequence in the distal region of the PRL promoter used in the present study or may be involved in PRL promoter regulation in an indirect manner.
In addition to PRL promoter activity, basal and forskolininduced proliferation of lactotrophs was greatly inhibited by MCREB expression, suggesting requirement of CREB for both basal and cAMP-induced lactotroph proliferation. These results are the first to imply involvement of CREB in the regulation of lactotroph proliferation. CREB activated by the cAMP-PKA pathway may upregulate expression of its target genes, including c-fos, cyclins, and proliferating cellular nuclear antigen to stimulate lactotroph proliferation. However, Struthers et al. (37) reported that transgenic mice expressing MCREB under the control of the growth hormone promoter had a dwarf phenotype with a marked deficiency in somatotrophs and that, although lactotrophs in the transgenic mice also expressed the mutant CREB, lactotroph cell densities in the anterior pituitary were apparently normal. These findings in transgenic mice seem inconsistent with those in the present study in which the same dominant-negative CREB mutant was expressed in cultured rat pituitary cells. Presently, the reason for this discrepancy remains unknown. Lower expression of MCREB in lactotrophs than in somatotrophs, due to expression regulation by the growth hormone promoter, may be insufficient to suppress lactotroph proliferation. The development of transgenic mice that express MCREB under the direction of the PRL promoter may be helpful for testing this view.
We showed that MCREB expression markedly inhibited IGF-I-induced lactotroph proliferation. This finding raised the possibility that IGF-I may activate the cAMP-PKA-CREB pathway to stimulate lactotroph proliferation. We addressed this possibility and found that IGF-I did not alter intracellular cAMP concentrations but stimulated CREB phosphorylation in lactotrophs to a limited degree. This is in agreement with the findings of other studies that growth factors cause Ser 133 phosphorylation of CREB via ribosomal S6 kinase 2 (8, 44), MAPK-activated protein kinase 2 (31, 40), or mitogen-and stress-activated protein kinase 1 (7). The cAMP-independent activation of CREB by IGF-I in lactotrophs suggests that CREB partly mediates the mitogenic signal of IGF-I in lactotrophs. However, considering our previous findings that even inhibition of PKA, which is upstream of CREB activated by IGF-I and is not affected by IGF-I, suppressed insulin-induced lactotroph proliferation, it seems likely that, in addition to CREB activation, the mitogenic action of IGF-I or insulin on lactotrophs requires basal activity of the cAMP-PKA pathway at an unidentified step of growth factor signaling.
Hypothalamic dopamine exerts a profound effect on many lactotroph functions, including cell proliferation, synthesis and secretion of PRL, apoptosis, cell morphology, intracellular Ca concentration, and membrane potentials (1). The signal transduction pathways mediating many of the cellular responses of lactotrophs to dopamine have not been fully determined and are unlikely to involve a common mechanism. The primary mechanism by which dopamine inhibits PRL gene expression seems to be inhibition of adenylate cyclase activity and the subsequent cAMP-PKA pathway (11, 27, 28, 39) , although other signaling pathways mediated by protein kinase C (4), Pit-1 (23), and ERK (25) have been proposed for the dopamine inhibition. In contrast, the mechanism of the antimitogenic action of dopamine is less well understood. Therefore, we tested the hypothesis that dopamine inhibits PRL promoter activity and lactotroph proliferation by inhibiting the cAMP-PKA-CREB pathway. First, we showed that bromocriptine inhibited basal and forskolin-induced CRE-luciferase activity and lactotroph CREB phosphorylation. Second, MCREB expression, mimicking suppression of CRE-mediated transcription and CREB phosphorylation observed in the bromocriptine-treated lactotrophs, inhibited lactotroph proliferation and PRL promoter activity. These results support the idea that inhibition of CREB activity is responsible for the dopamine inhibition of both PRL promoter activity and cell proliferation in normal lactotrophs.
